CAP

Mutual funds and safe government bonds: do returns matter?

Retrieved on: 
Thursday, April 25, 2024
ACT, Safe Haven, Research Papers in Economics, Flight, Policy, B.3, ICAPM, RT, Journal of International Economics, Krishnamurti, Business, CIP, International, Observation, P25, Safety, A23, Benchmarking, B.2, FX, Paper, TSD, Environment, Journal of Financial Economics, Bogdanov, Federal, Website, United, A14, Total, The Economic Journal, Eurozone, Face, G11, Quarterly Journal of Economics, Interest rate parity, History, WD, Investment, Liquidity premium, Politics, OLS, Statistics, G15, Caballero, PDF, Classification, ECB, Foreign exchange market, AC, P99, Federal funds, Froot, Lethargy, Social science, Interest, JEL, Bias, Journal, Research, Journal of Economic Literature, The Journal of Finance, E.3, Literature, Federal Reserve, Parity, European Central Bank, AA, Annual Review, Growth, Bank of England, FRED, S&P, Injection, Risk, Elasticity, Government, G12, Finance, BIS, S1, JL, E.1, Money, Depreciation, Asset, Treasury, Federal Reserve Economic Data, A11, A10, R2, Section 4, UMP, A4, Boj, Section 3, Accounting, SJ, Fed, Mutual fund, Lustig, University of Lausanne, Section 2, P75, Foreign-exchange reserves of India, Assets under management, A19, GBP, FE, American Economic Review, A22, E.5, A3, A21, Flight-to-liquidity, Aggregate demand, G23, WT, USD, Autocorrelation, CAD, UIP, Currency, XR, Quarterly Journal, Appendix H, Capital, P95, A6, Zhu, University, B.1, P50, CHF, Transmission, Swings, Estate (law), EUR, Bank for International Settlements, JPY, E.4, Central bank, Multicollinearity, Bank, Fixed effects model, Reproduction, CAP, The Atlanta Jewish Times, VIX, Data, Om, Lobster
Key Points: 

    Press release - Opening: 22-25 April plenary session

    Retrieved on: 
    Tuesday, April 23, 2024
    Freedom, Intelligence, Agriculture, Risk, Climate, Novel, CAP, Parliament, Commission, Council, Energy, Human

    - Swedish nationals held in Iran

    Key Points: 
    • - Swedish nationals held in Iran
      - Last plenary before the elections
      President Metsola opened the 22-25 April plenary session in Strasbourg with the following announcements.
    • Parliament once again condemns their arrest by the Iranian regime in the strongest possible terms, and will continue to work to secure the release of all those held on trumped up-charges.
    • The vote on Simplification of certain CAP rules will take place during the second voting session on Wednesday afternoon.
    • Contacts:
      Andreas KLEINEREditorial Coordinator / Press Officer (DE)
      Estefanía NARRILLOSEditorial Coordinator / Press Officer (ES)
      Natalie Kate KONTOULISPress Officer

    Press release - European Parliament Press Kit for the Special European Council of 17 and 18 April 2024

    Retrieved on: 
    Thursday, April 18, 2024
    Gas, Hamas, Face, ACI, Committee, Special, Seal, S&D, Parliament, Council, Investment, Honey, European Commission, EP, Data Act, Artificial intelligence, Policy, Legislation, Wildfire, Research, War, Delegation, Communication, Speech, Democracy, CFD, Aggression, Poultry, Partnership, Risk, Outline, City, MFF, Brexit, Safety, GAEC, GUE/NGL, SMEI, Pilar del Castillo, Waste, SME, STEP, Weather, Person, Emergency, Electricity, Annual report, Climate change, International trade, Acceleration, Intelligence, Act, Internet, Coercion, AI, Crime, Private sector, Commission, Common Agricultural Policy, Nuclear energy, Security, Single market, Grid, Violence, Mining, Civil service commission, Punishment, EUR, Cyber, Farmer, European Council, Artificial Intelligence Act, EPP, Recycling, European Parliament, COVID-19, Common, CAP, Flood, Hydrogen, EBS, European Defence Fund, Collection, International law, Defense, Government

    In this press kit, you will find a selection of the European Parliament’s press releases reflecting MEPs’ priorities for topics on the summit agenda. Source : © European Union, 2024 - EP

    Key Points: 


    In this press kit, you will find a selection of the European Parliament’s press releases reflecting MEPs’ priorities for topics on the summit agenda. Source : © European Union, 2024 - EP

    The Port Authority of New York and New Jersey selects Locus Technologies Cloud Software for GHG Management

    Retrieved on: 
    Tuesday, April 9, 2024
    Diamond, Software as a service, Waste management, Biophysical environment, GHG, ESG, Software, CAP, Locus Technologies, Record, Carbon, Ship, Sustainability, Port authority, Aircraft, EHS, Environmental Health (journal), Renewable energy

    The expansion will include a comprehensive application to capture operational and organizational greenhouse gas (GHG) and criteria air pollutant (CAP) emission inventories from all Port Authority activities.

    Key Points: 
    • The expansion will include a comprehensive application to capture operational and organizational greenhouse gas (GHG) and criteria air pollutant (CAP) emission inventories from all Port Authority activities.
    • This application will expand the Port Authority’s current Locus applications for construction sustainability and waste management.
    • Locus provides clients powerful software tools to track and manage various emissions streams.
    • “We are excited that the Port Authority selected Locus Technologies for their ambitious goal of tracking all carbon emissions, including all construction activities.

    Clartias Chief AI Officer Rex Briggs to Keynote Possible

    Retrieved on: 
    Tuesday, April 9, 2024
    Progressive Corporation, University, Learning, Integration, Social media, Marketing, Microsoft, Council, IAB, SVP, WIRED, Face, McDonald's, MIT Press, NPR, Ad Council, CMOS, ROI, Digital, Corporation, Internet, CNBC, AI, Ad Age, Book, Daniel Yankelovich, ANA, Digital marketing, Algorithm, MIT, Software, CNN, CAP, Bloomberg, Possibility, Economist, Hall, Interactivity, Management

    Cincinnati, Ohio, April 08, 2024 (GLOBE NEWSWIRE) -- Claritas ®, a data-driven marketing leader that leverages a proprietary identity graph to help marketers achieve superior ROI, today announced that its Chief AI Officer Rex Briggs will deliver a keynote discussion at Possible 2024.

    Key Points: 
    • Cincinnati, Ohio, April 08, 2024 (GLOBE NEWSWIRE) -- Claritas ®, a data-driven marketing leader that leverages a proprietary identity graph to help marketers achieve superior ROI, today announced that its Chief AI Officer Rex Briggs will deliver a keynote discussion at Possible 2024.
    • In addition to Briggs, other speakers at Possible 2024 include: Linda Boff, GE Chief Marketing Officer VP, Learning & Culture President, GE Foundation; Esi Eggleston Bracey, Chief Growth & Marketing Officer, Unilever; Tariq Hassan, Chief Marketing & Customer Experience Officer, McDonald's Corporation; Diana Haussling, SVP - GM Consumer Experience and Growth, Colgate-Palmolive;  Linda Lee, Chief Marketing Officer, Campbell’s Soup; Frank Cooper III, Chief Marketing Officer, Visa;  Remi Kent, Chief Marketing Officer, Progressive Insurance; David Droga, Chief Executive Officer, Accenture Song; Soyoung Kang, Chief Marketing Officer, Eos; Dana Marineau, Chief Marketing Officer, Rakuten; Bozoma Saint John, Hall of Fame Inducted Marketing Executive, Author, and Entrepreneur; Jaime Teevan, Chief Scientist, Microsoft and Gary Vaynerchuk, Chairman, VaynerX.
    • During Briggs’ work with the Ad Council, he discovered ArtsAI and experimented with its patented AI Personalization technology.
    • In his latest book, “The AI Conundrum” (MIT Press), Briggs and co-author Caleb Briggs explore why artificial intelligence’s strengths are also AI’s weaknesses – and how businesses can effectively apply AI to improve their business.

    Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

    Retrieved on: 
    Monday, April 8, 2024
    Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

    Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

    Key Points: 
    • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
    • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
    • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
    • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

    bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results

    Retrieved on: 
    Monday, April 1, 2024
    Medical Devices, Surgery, FDA, Genetics, Clinical Trials, Biotechnology, Radiology, Pharmaceutical, Health, Oncology, Research, Lung cancer, Growth, CFO, Laboratory developed test, Form, Patient, Accounting, Bronchoalveolar lavage, Sale, Acquisition, Cancer, CPA, CAP, Insurance, MBA, Lung, BAL, BIAF, Bronchoscopy, LDT, Optimism, Medicare, Calendar, Marketing, CMS, Physician, Pharmaceutical industry

    Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.

    Key Points: 
    • Revenue for the fourth quarter of 2023 was approximately $2.2 million, up from no revenue for the prior-year period.
    • Research and development expenses were $432,000 for the fourth quarter of 2023, compared with $429,000 for the comparable period in 2022.
    • Selling, general and administrative expenses were $2.2 million for the fourth quarter of 2023, compared with $1.2 million for the comparable period in 2022.
    • Net loss for the fourth quarter of 2023 was $2.4 million, compared with a net loss of $1.7 million for the comparable period in 2022.

    Nucleus Genomics launches to bring whole-genome sequencing to the public

    Retrieved on: 
    Monday, March 25, 2024
    Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

    Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

    Key Points: 
    • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
    • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
    • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
    • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

    Spectrum Solutions® Releases the New SimplyPERIO™ Saliva Test Powered by SimplyTest®

    Retrieved on: 
    Thursday, March 21, 2024
    Medical Devices, Hospitals, Dental, Health Technology, Practice Management, Biotechnology, Other Health, Health, General Health, Temperature, Radioactive decay, Science, USPS, Infection, Disease, Fungus, Peri-implantitis, Central nervous system, Inflammation, Third party, CAP, Patient, Doctor of Philosophy, Artery, Periodontal disease, Saliva, Immunity, Mouth, Heart, Gingivitis, Collection, Dentistry

    Spectrum Solutions ®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™.

    Key Points: 
    • Spectrum Solutions ®, saliva diagnostic biotech leader, today announced the official release of a new saliva diagnostic testing innovation, SimplyPERIO™.
    • In addition, gum disease decreases a person’s ability to fight infection and inflammation.
    • SimplyPERIO™ uses a proprietary molecular technology to test for and measure periodontal bacteria, caries, fungal and viral targets all for one affordable cost.
    • “We are using science to make saliva diagnostics simple for both Patients and Providers.

    Inocras Inc. Unveils Rebranding of Genome Insight

    Retrieved on: 
    Monday, March 18, 2024
    Technology, Neurology, Genetics, Biotechnology, Other Health, Health, Data Management, Artificial Intelligence, Oncology, Disease, Patient, Research, Cancer, AI, CAP, CLIA, Whole genome sequencing, Nursing care plan, Antibiotics

    Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.

    Key Points: 
    • Inocras, formerly known as Genome Insight, announced today its rebranding initiative to reflect its commitment to innovation and user-centric healthcare solutions.
    • The AI-driven whole genome platform company, specialized in whole genome sequencing and analytics for cancer and rare diseases, has embarked on its rebranding to reinforce its dedication to shaping an "innovative tomorrow".
    • The rebranding accentuates its focus on "user-centric approaches" for patients, providers, and researchers, surpassing the provision of sequencing and analytics services.
    • Inocras Inc. (formerly Genome Insight Inc.) is a pioneering provider of whole genome sequencing and analytics services for cancer and rare diseases.